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INTRODUCTION 
Medulloblastoma  is the most common malignant  brain  tumor  of  
childhood  with an annual incidence of about 0.5-0.8 / 1,00,000  in 
children,  younger  than  19  years of age(1) (22)  . It is relatively less 
common in adults. The incidence in adult is 0.5 per 100,000. (11) It is 
the second most common type of pediatric brain tumors (16). (Low 
grade gliomas are the first commonest pediatric brain tumors, which 
constitutes 35-50%).  It is a highly invasive, malignant embryonic 
tumor. Historically, it has been classified as a primitive neuroectodermal 
tumors (PNETs), but now, it is no longer  considered as a PNET entity.  
It is a member of small blue round cell tumors. Mostly it occupies the 
posterior fossa, or cerebellum. (15).  
It constitutes about 40% of all posterior fossa tumors. The other 
tumors of posterior fossa are ependymoma, astrocytoma, brainstem 
glioma and metastases (34). Currently medulloblastomas are thought to 
arise from cerebellar stem cells that have been prevented from dividing 
and differentiating into their normal cell types.  
Medulloblastoma is seen like   filled with   small ovoid cells, 
which have a darkly stained   hyper chromatic nuclei and frequent 
mitoses. Other  members  of  small  blue round  cell  tumors  are  
Ewing’s  sarcoma , Rhabdomyosarcoma,  Synovial sarcoma, 
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Hepatoblastoma,  Neuroblastoma,  Retinoblastoma,  and  Non-
Hodgkin’s  lymphoma(31) . Both  periventricular  pseudo rosettes and  
Homer Wright  rosettes (clustered  cells surrounding  central  
eosinophilic  core)  are highly characteristic of medulloblastoma  and  
seen  in  half of  the cases. It is told that the cancer stem cells are 
present in the perivascular niche. 
The commonest   age group affected in adult is 20-40 years, (16) 
and it is   mostly eccentrically placed in posterior fossa (50%).  Adult  
medulloblastoma  are  frequently desmoplastic variant, and  the  
presence  of  severe  anaplasia  is  also less in adult medulloblastoma. In 
children it  accounts for 3% of total pediatric cancers and 10-20% of 
brain  tumors.It is   mostly  centrally  placed  tumor  in cerebellar region  
and floor of 4th ventricle , adverse prognostic factors include  1)male 
gender and 2) age less than 3 years. Patients with surgical excision of 
tumor either near- totally or totally, fare better than those with partial 
excision or biopsy only. 
The male : female ratio worldwide  is 2:1.The incidence  of  
medulloblastoma is higher  in  males  and higher in early childhood(16), 
(22), almost half of the cases occur  before age of 5 (34).Established 
prognostic  variables accepted  by North American Children Oncology 
Group ( COG) and the    SIOP ( international  society  of  pediatric  
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oncology )  group  : Patients are classified as  average risk and high risk  
groups. 
If the  age is  > 3 years ,if patient has < 1.5 cm2  ( maximum  
cross  sectional area) of  residual  tumor  and  no  dissemination it is 
considered as standard risk category.  
If patients with age > 3 years, > 1.5 cm2 of residual tumor and/ or 
evidence of CSF dissemination or < 3 years of age at diagnosis,they  are 
considered  as high risk. Children less than 3 yr of age , hemispheric 
location, high risk according to risk stratification, and patients who do 
not receive radiation therapy affected the prognosis- in univariate 
analysis. In multivariate analysis, hemispheric location and high risk 
influenced death.(3) 
Syndromes   associated with medulloblastoma are Gorlin 
Syndrome (18), (19), (38) and Turcots Syndrome (18). Gorlin  syndrome 
is  also  known  as  nevoid  basal cell carcinoma syndrome,/  gorlin - 
goltz syndrome .It  is an inherited condition with multiple body systems 
involvement  such as multiple basal cell carcinoma, in face ,arm, and  
trunk(skin), microcephaly, medulloblastoma (nervous system), ovarian 
fibroids (endocrine system) and  frontal bossing, bony cysts, 
kyphoscoliosis, bifid ribs and small metacarpals bones (38).  Risk of 
death in Gorlin syndrome due to medulloblastoma is 50% if the   age is 
less than 4 years. 
 4 
Turcot syndrome is characterized by multiple adenomatous 
colonic polyps with an increased risk of colorectal cancers, and   brain 
tumors (19). CSF dissemination  may  manifest  as  positive  cytology  
or   macroscopic seeding  of  the  sub arachnoid  space .It  is  not a 
common manifestation . Only 30-40% of cases present with CSF spread 
at the time of presentation and diagnosis. Systemic spread is mostly to   
bone and bone marrow (15). This pattern of spread is considered in the 
analysis of dissemination in CHANG staging. 
Medulloblastoma is clinically classified by Chang et al in 1969 
based on size and invasiveness of tumor as determined intra operatively 
and on the presence of metastases. But, Chang staging is no longer used 
now, although elements from it form current clinical risk stratification. 
Chang staging is   helpful   to   differentiate standard risk patients and 
high risk patients. M0 is without any metastases anywhere. M1 stage is 
presence of tumor cells in cerebrospinal fluid (CSF). It can be seen in 
MRI or by CSF cytology. M2 is having gross nodular seeding in 
cerebellar sub arachnoid space, cerebral subarachnoid space, third  
ventricle and fourth ventricle, i.e. other  than the  primary  site intra 
cranially. M3 stage consists of gross nodular seeding in spinal 
subarachnoid space. M4 is extra neural metastasis. 
The world health organization (WHO) (34) pathological 
classification of brain tumors includes 5 subtypes of medulloblastoma.  
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Histologic subgrouping includes classic,   desmoplastic, large cell, 
anaplastic and medulloblastoma with extensive nodularity variety. 
Classic   medulloblastoma    constitutes   the   commonest   
histology   (66%), and   it   is       composed    of sheets of closely   
packed   small   blue   round   cell with   a   high  nuclear to cytoplasmic 
ratio, mitotic and apoptotic activity.  It may occur mostly   in    midline.  
Desmoplastic and nodular varieties  constitute 15% of total 
occurrence . Desmoplastic  variety  carries a  favorable  prognosis,  and  
it  may  arise  laterally in cerebellar hemispheres. This variety   
compromise small    blue   round   tumor cells     typically   harbor   
reticulin rich stroma   with   reticulin free pale islands, which are 
immune positive for synaptophysin indicating neuronal differentiation. 
Cells show glial fibrillary acidic protein immunopositivity. 
Recently a consensus conference in Boston in 2010 supported 
classification of 4 main subgroups of medulloblastoma on the basis of 
molecular genetics. Integrated  genomic  studies  revealed  
medulloblastoma   into  4  distinct  molecular  and  clinical  variants,  
termed  WNT/ ( beta Catenin), SONIC HEDGEHOG, GROUP 3 AND 
GROUP 4 (33). The Wnt and Shh groups are named after the 
predominant signaling pathways thought to be affected. Cytogenetic 
abnormalities found are loss of 17p, amplification of    MYC-C,   and   
amplification of MYC-N. As advances in the molecular and   genetic 
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profiling of   pediatric   medulloblastoma evolve, associations with 
prognosis and treatment are found. (34) It is noted as mentioned below:  
WNT subgroup of medulloblastoma  arises  from lower rhombic 
lip of 4
th
 ventricle especially   from mossy neuron fiber precursors. It 
carries a very good long term prognosis (90%). It is the rarest molecular 
type. The Wnt pathway inhibitor APC gene predispose to turcots 
syndrome. (19). Wingless is a family of growth factor receptors that are 
involved in embryogenesis and in “cell to cell” control mechanism. The 
histology of this subgroup   is usually Classic histology, which is 
positive for IHC- beta catenin staining, CTNNB1 mutation which 
encodes for beta catenin and PTCH mutation. It is associated with loss 
of chromosome 6 and rarely expresses chromosome 17 aberrations.  
Sonic hedgehog subgroups accounts for 28% of all 
medulloblastomas. It arises from external granular layer of cerebellum. 
It can be identified by transcriptional profiling, IHC staining for SFRP1. 
It is of  interest  because  of  the  availability  and  temporary success of 
(SMO )small  molecular  inhibitors. The subgroups   frequency is less 
between 3-16 years of age group. Nodular / desmoplastic histology is 
present. Aberrant SHH signaling in normal human development may 
cause holoprosencephaly. SHH ligand is normally secreted by purkinji 
neurons. Prognosis is “in between” WNT (good) and group 3 (poor).  
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Group 3 or Group C subgroup   mostly has the histology of   
classic  medulloblastoma.  It has a male preponderance than for females. 
One peculiar issue is it is almost never observed in adults. It is notorious 
for frequently metastatic, recurrence and death occurrence. It carries a 
poor prognosis due to be presence of MYC amplification.  It is the more 
specific point in prognosis. 
Group 4 or Group D   subgroup is most   common   typical   group   
of   medulloblastoma. In frequency of occurrence it is accounting    for   
34% .The    peak   age of occurrence is   10    years.   It   is   considered    
as  prototypical   medulloblastoma.  KCNA1 is an IHC marker of group 
4 variety. It has   tendency to have is chromosome 17 q   and Loss of X 
chromosome. 
It’s  aggressive  pattern   of    growth  , it’s    tendency of   lepto    
meningeal  spread  and  drop metastasis  in  cauda  equine  regions, 
create the need for intensive combined modality therapy.  The survival 
rates depend upon age groups and histology, which is 60%, 52%, and 
47% at 5 years, 10 years and 20 years respectively.  
In treatment  aspect , all  the  localized  tumors  must  be  excised  
with  maximum   safe   resection,  no margins   are   needed  because 
knife is not supposed to be put in normal brain.  Sometimes,   brainstem    
involvement may present, which stops from complete resection. In 
surgical treatment method, patients have to undergo ventriculo -
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peritoneal shunt and   excision of intracranial tumor. Near total excision 
or total excision of the intracranial tumor is preferred than the subtotal 
excision. When there is an obstruction to flow of CSF due to the 
presence of tumor, patients need to undergo ventricular peritoneal shunt. 
When obstruction is removed, the increased intra cranial tension is 
relieved. Patient gets relieved from headache, vomiting and blurring of 
vision after this surgery. 
Posterior  fossa syndromes(40)  is the  development of collection 
of neurological  symptoms  like  dysphagia,  trancal ataxia, hypotonia  , 
mutism, respiratory  failure, cranial  nerve deficits, neurobehavioral 
changes and urinary retention or incontinence  after  posterior  fossa  
craniotomy  for  medulloblastoma tumor excision. It is also called 
“cerebellar mutism” It occurs in 10-15% of children after posterior fossa 
resection. 
Post-operative radiotherapy should begin within 28-30 days after 
resection, whenever it is possible. Radiation   should be given to   whole 
of spine and cranial fields. It must be followed by a boost of radiation to 
full of   posterior fossa of brain, using opposing lateral fields. Multiple 
fields can also be used to spare cochlea.  
We can go for simple opposing posterior obliques for posterior 
fossa. Adults can be given radiation to cranio-spinal fields up to 36 Gy, 
because of  the lesser incidence of neural and cognitive impairment in 
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adults (25). Comparatively, children are prone for more long term 
complications   of   nervous system like irritability, growth defects,   
delay in secondary sexual characters development (7), etc. Pediat ric 
cases can be treated with 23.4 Gy cranio-spinal irradiation (13), as long 
as appropriate chemotherapy is given along with it.  
The total  dose to posterior fossa must be 45-50 Gy for spinal 
metastatic conditions and it can be proceeded up to 50-54 Gy in case of 
intra cranial metastases. Treatment daily dosage is 1.8 Gy single 
fractions. Radiation to cribriform plate region is also important to 
prevent recurrence. (41).  It is  told  P13 K  pathway  regulates  the  
survival  of  cancer  stem  cells, residing   in   perivascular   niche   
following   radiation   in   medulloblastoma in  vivo(42).Posterior fossa  
boost  can  be done  better  with  3DCRT  and  planning is done  with  
CT/ MRI. It is said hyper fractionation reduces the   delayed   
complications.Non CNS tumors can occur in ares which received 
radiation. Gliomas can occur. 
Adult patient’s tolerance for chemo is very poor. PCV regimen is 
one which is widely used along with weekly inj.vincristine 1.4mg /m2. 
Targeting   with agents  like cyclopamine (35) vismodegib (36) (GDC- 
0449) and saridegib(37) were  being given.  
 10 
As a general rule, adult patients also   must be treated with same 
treatment modality like pediatric   patients,    but    poor tolerance is 
encountered at many times during 
treatment with weekly inj. Vincristine. Also the role of 
chemotherapy  in adult   is not yet proven clearly, as it was proven in 
pediatric cases.  The 10-year over all survival reported was 53% and the 
10-year progression-free survival was 40%. 
The occurrence of complications may be seen in  a spectrum of 
expressions. 
It can be acute or long term. Pubertal delay (7) is one of the  
common complications, intellectual incompetence also often 
encountered as a long term complication (6). Half of patients required a 
long-term thyroid hormone supplementation. Growth hormone 
administration may be needed. Often sex   hormone replacement may be 
needed in many patients. Deficiency of ACTH and diabetes insipidus 
were seen in very few of the patients. Older patients show a delay in  
declination  of performance, younger children show immediate loss of 
performance(6) 
At the time of follow-up, one third of patients may have short 
stature with < 3
rd 
percentile. Few patients have obesity, their body mass 
index will be > 97
th
 percentile. Patients had reported with significant 
 11 
alopecia, mainly seen in occipital region of scalp. Mainly because of 
their alopecia, patients were highly dissatisfied with their physical 
appearance . It is  important to minimize the treatment related toxicity  
(9). 
Nearly half of the   patients    reported  about significant   
perioperative neurological complications that persisted during long-term 
survival follow-up.These complications included   facial   nerve   palsy, 
strabismus, hearing  impairment  and visual impairment, hemiparesis 
and tetra paresis. Almost all patients had significant neurocognitive mal 
functioning: Attention impairment and delay in processing speed , 
learning impairment and memory impairments were present in    some   
patients.   
Language  impairments, visual perception   impairments    and   
executive function impairments also present in patients. Significant 
impairments in overall level of  the  intellectual functioning  (IQ < 85) 
was seen in many patients.  In patients who did not receive any 
radiotherapy, language impairment is present, but the overall level of 
intellectual functioning in them was normal. Patient  experienced 
significant problems in school.Many of the patients are   studying in 
special school. Few   patients do attend regular schools, but  they need 
remedial teaching. 
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Several patients complained about their   inability to  concentrate   
and about difficulties with comprehension and delayed speed of 
working.  Among patients of employable age, very   few   are able to 
follow a   professional training in  specialized institution, half of   them   
are   unemployed   at the time of survey. Many of the patients were not 
able to take up their preferred job because they were unable to obtain 
the required qualifications. Their   friendships mainly turned out to be 
not very strong and many survivors do not have any friends at all. 
Patients reported difficulties in making friends. While the grave 
prognosis associated with medulloblastoma is fully justifiable, it appears 
that some hope can be given to parents, since practically 40 % of our 
cases completing treatment have survived 5 years , and 30% , 10 
years.(8). 
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containing regimen had median survival of 16.5% smoothened inhibitor 
trials had median ORR of 8%.temozolamide is the backbone of newer 
chemo regimens 
22. Medulloblastoma in childhood: an epidemiological study, 
farwell JR et al J Nuerosurg 1984 . A relationship between polio 
vaccine infected with SV40 virus and medulloblastoma development. 
Children with medulloblastoma have increased number of family 
members with brain tumors , leukemia or childhood cancers.  
23.Quality of life for survivors children irradiated for brain 
tumor before the age of 4 years: jenkin et al . med pediatric oncol 
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1998 10 year survival rate was  40%,. 54 % of survivors didn’t harbor  
any major neurological, visual or hearing defects. Among adult 
survivors, older than 21 yrs, have complted higher education 26%. 31 % 
were in full time employment. 37% hadnever employed. Search for a 
less toxic treatment is appropriate.  
24.Quality of long term survival in young children with 
medulloblastoma, jonson et al. J Nuerosurg 1994    23 families were 
interviewed by telephone among them 13 came to hospital, I Q  was less 
than 90% for all participants,pt who undergone shunting had more test 
scores in reading, spelling and mathematics. Perceptual motor task 
performance were poor in 50% of participants. Problem in learning and 
delay in physical growth  anddevelopment seen in majori ty of patients. 
25. Brandes et al, long term results of prospective phase 2 trial 
of adult medulloblastoma: treated with neoadjuvant chemotherapy 2 
cycles followed by radiation and followed by chemotherapy again. 
median followup of 7.6 years, 5 year overall survival rate 75% , ( for 
high risk patients – 73% and average risk patients- 80%) and 
progression free survival rate 72% ( for high risk patients 69%. For 
average risk patients- 80%) 
26.Duffner et al. (1993) : assessed whether RT can be delayed by 
giving chemo post operatively and delay in RT until > 3 years age. 
Chemo given was  2 cycles of cyclophosphamide and vincristine 
 21 
followed by 1 cycle of cisplatin and etoposide. RT given was CSI 35.2 
gy and posterior fossa dose 54 gy. Study saysit is safe to delay RT until 
the age > 3 years. 
27.P9934 trial : combination chemotherapy followed by second 
look surgery and radiation therapy in treating children with 
nonmetastatic medulloblastoma or primitive neuro ectodermal 
tumors, august 2013 – children oncology group-  to determine the 
treatment for 8 months to 3 years of age group. It allows feasibility of 
telephone interview of patients based on data collection method for 
neuropsychological evaluation.( drugs used cisplatin, cyclophosphamide 
and etoposide) 
28. COG ACN 0331 trial :Children oncology group- involved 
field RT and low dose craniospinal irradiation with chemotherapy in 
average risk medulloblastoma, says , survival rates of reduced RT 
boost volumes were comparable to standard treatment volume for the 
primary site of tumor. There is no survival difference between both 
techniques. Reduced dose to craniospinal axis associated with higher 
event rates and worst survival. 
29.ACNS 0334 trial :for the treatment of newly diagnosed 
supratentoreal PNETs and high risk medulloblasoma children more 
than 3 years of age intensive induction chemotherapy with 
methotrexate followed by consolidation stem cell rescue  
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30. neuropsychological sequel of the treatment of children 
with medulloblastoma , july 1996, Maureen dennis, Brenda 
j.spiegler, c.ross Hetherington : survivors have long term deficits in 
intelligence, memory, language, attention, academic skills, 
psychological function, and a compromised quality of life. Age at 
diagnosis and time since treatment are important contributors of 
intellectual morbidity. These children progressively fail to assimiliate 
new verbally based knowledge at a developmentally appropriate rate.  
31. the perceived impact of cancer on quality of life for post 
treatment survivors of childhood cancer, brad j zebrack, wendy 
landier, march 11, 2011 – says quality of life and distress are partially 
a function of survivors perception of how cancer has affected them and 
continues to affect them both in positive and in negative ways.  
32.http: // www.ncbi.nlm.nih.gov/pmc/articles/ PMC3167982/ 
small blue round cell tumors.j am Podiatr Med Assoc. 2011 jul-aug ; 
363-9, small blue round cell tumors. 
33.Molecular classification of medulloblastoma : Sarah ES 
Leary.2012 james m oslan,, journal of clinical oncology, official journal 
of American Society of clinical oncology 2011; 29_ 1424-1430. 
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34.Pediatric medulloblastoma- update in molecular 
classification driving targeted therapies- ruth-mary desouza,benjemin 
R.T.jones front oncol 2014,4: 176, july 22 2014.  
35.Thyroid dysfunction as a late complication of childhood 
medulloblastoma : a comparision between hyper fractionated RT vs 
conventional RT, Umberto ricordi, andre corries,silvia finaudi, 
international journal on radiation oncology* biology* physics 50 
(5),1287-1924.2001:  hyperfractionation can reduce the delayed effects 
of radiation injury. 
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AIMS AND OBJECTIVES 
This study is conducted to evaluate the medulloblastoma patients 
who attended the treatment in department of radiation oncology , madras 
medical college , chennai, during the period january 2000 to  December 
2010 in respect to agewise and  genderwise distribution,  tumor site wise  
and histological subtype of tumor wise survival analysis  , treatment  
modalities undergone and their survival rates .  
AIM OF THE STUDY 
 To study the long term outcome of medulloblastoma patients, who 
were treated in our institution during the period 2000-2010 
 It is a retrospective study with available clinical record and 
patients follow up 
 Outcome analysis was done with respect to  
o Age and sex distribution 
o Tumor location 
o Clinical presentation 
o Treatment modalities 
o The response to treatment 
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MATERIALS AND METHODS 
DISCLOSURE:   This study was done purely in the government 
hospital after obtaining    the   consent   from   individual   patients. The   
Tamil consent form is   attached. The   Ethical committee   clearance   
was   obtained   prior to this study. The study was often reviewed and 
presented periodically in the department during the course. 
Estimation  of  sample  size:  sample  size  could  not  be  
predicted  by  significance   levels   and  error  estimations. It is done 
with total coverage of 10 year period from 2000 to 2010. All  the  
patients  were  included  and  the  total  number  becomes  the  sample  
size. 
CRITERIA FOR INCLUSION IN STUDY 
We include three criterias of inclusion,  
 All cases must be a biopsy proven medulloblastoma patients. 
 They should be registered in department of radiation Oncology, 
RGGGH,Chennai 
 The treatment period should be between January 2000- 
December 2010. 
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CRITERIA FOR EXCLUSION IN STUDY 
 Patients without HPE documentation 
 Patients who undergone treatment at other institutions.  
DATA COLLECTION 
Year 
Cases of nervous 
system 
Madulloblastoma 
cases 
2001 127 7 
2002 98 7 
2003 139 8 
2004 123 3 
2005 111 10 
2006 89 3 
2007 88 5 
2008 128 12 
2009 124 8 
2010 99 9 
Case  records of  medulloblastoma  patients  who  were  treated  
during  the  period  2000 - 2010  were collected from MRD. Totally 
18,213 case sheets were analyzed during the study period and 75 
patients of medulloblastoma were included for the study.  
Majority of them were lost for follow up. During that treatment 
period (2000-2010), mobile phone facility was very much limited. Some 
patients had given   partial    addresses only, so we were not able to 
trace their address. Permission obtained  from  all  the   three 
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oncological department, (medical  oncology , surgical oncology  and  
radiation oncology ) and pooled  data  of  these  patients  were  arrived. 
With  the  help of  NGOs, village  health  nurse  surveillance, volunteers  
75 patients  location  and  survival status were known, within   6 months 
period. 
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RESULTS 
GENDER DISTRIBUTION  
Among the 75 cases reported, males constitute 56% and females 
constitute 44%. i.e. total  number of  males treated was 42  and  the  
total  number  of  females treated was  33. 
Number of male 
treated during 2000-
2010 
Number of females 
treated during 2000-
2010 
Total persons 
treated during 2000-
2010 
42 (56%) 33(44%) 75(100%) 
AGE WISE DISTRIBUTION 
 
Total number of patients reported in the age group of 1-3 years, 
was 13. (6 male and 7 female). In 4-12 years of age, 39 cases were 
reported (25 male and 14 female). In 13- 18 years of age, 12 cases were 
reported (4 male and 8 female). Less than 19 years of age group, 11 
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cases were reported (7 male and 4 female). The total number of male 
was 42, and female was 33. 
 The earliest age at presentation was 3 months (female baby).  
 The maximum age at presentation was 35 years ( 1 male and  1 female) 
 Maximum cases reported in “ 4- 12 years “ category ( 25 males 
and 14 females) 
 Male : female ratio was 4: 3 ( 42 male : 33 female )  
The distribution according to staging (CHANG   STAGING) 
Stage Description No of patients 
M0 No evidence of subarachnoid metastasis 65 cases 
M1 Tumor cells in CSF 3 cases 
M2 Intracranial tumors beyond the primary site 5 cases 
M3 Seeding in spinal subarachnoid space 1 case 
M4 Extra neural spread 1 case 
Chang staging is helpful to differentiate between the standard risk 
and the high risk patients. M0 is without any metastases; - in our study 
we have 65 cases in M0 stage. M1 stage is presence of tumor cells in 
CSF. It can be seen in MRI or by CSF cytology. We have 3 cases in M1 
stage. M2 is having gross nodular seeding in cerebellar, cerebral 
subarachnoid space third and fourth ventricle, i.e. other than primary 
site intra cranially. We have 5 cases in M2 staging. M3 stage consists of 
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gross nodular seeding in spinal subarachnoid space, we have 1 case  
reported. M4 is extra neural metastasis. We have 1 case in M4 stage.  
CLINICAL FEATURES 
Symptoms of increased ICT 
Headache 78% 
Vomiting 73% 
Diplopia 52% 
Symptoms of Pressure Effect  
Ataxia 38% 
Non Specific Presentations 
Deviation of angle of mouth 6.6% 
Fever 6.6% 
Drowsiness 6.6% 
Involuntary micturition 2.6% 
Weakness of limbs 2.6% 
Tremors of hands  2.6 % 
 Nasal regurgitation 2.6% 
Seizures 9.3% 
Spectrum of clinical presentations is seen in medulloblastoma 
patients. The maximum number of patients presented with increased 
intra cranial tension features. Head ache is the commonest presentation 
(78%). Next comes vomiting (73%), which relieves the headache. 
Seizures  caused due to cerebral irritation in 9.3% of patients. Some 
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non-specific features also were present, deviation of angle of mouth due 
to 7 the nerve involvement, fever, drowsiness. They constitute 6.6% of 
clinical presentation. Involuntary micturition, weakness of limbs, 
tremors, nasal regurgitation were also present in 2.6%.  
 
LOCATION OF THE TUMOR 
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Only 21% of cases are seen as lateral tumors( i.e )15 patients had 
lateral tumors. They were 4 cases (2 male; 2 female) of pediatric age 
group and 11 adult patients (6 males; 5 females).  
Majority of tumors are seen in midline(81.3%). 60 patients had 
midline tumors , situated in vermin  of cerebellum or 4
th
 ventricle. 48 
patients (29 male;19 female)were in pediatric age group and 12 
patients(5 male ;7 female) were adults.  
 
34 male have midline tumors and 8 male have lateral tumors.  26 
females have midline tumors and 7 females have lateral tumors. Totally 
60 midline tumors and 15 lateral tumors we encountered. The p value is 
significant. (Less than .05) In these 34 male of midline tumors, we have 
29 pediatric cases and 5 adult cases. In 26 female cases 19 pediatric and 
7 adult cases present. In lateral tumors 15 patients, we have 8 male, 
which contains 2 pediatric and 6 adult cases. In 7 female cases we have 
2 pediatric and 5 adult cases. 
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Centrally   Located   
Tumors 
Laterally Located 
Tumors 
Gender Male Female Male Female 
Pediatric cases 29 19 2 2 
Adult cases 5 7 6 5 
Total  34 26 8 7 
 
HISTOLOGICAL VARIENTS 
Histologically we get 4  types. Classical variety, nodular variety, 
large cell   and desmoplastic varieties are   most common   group of   
histology. In classical   histology we got 40   patients.  They   constitute    
the   majority. In large cell/nodular histology, we get 13 patients. In 
desmoplastic type, we got 22 patients.  
No Type of histology Number of occurrence 
1 Classical 40   patients 
2 Large cell/nodular 13  patients 
3 Desmoplastic 22   patients 
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TREATMENT MODALITIES UNDERGONE 
The standard care comprises of tri modality approach (with 
surgery, radiotherapy and chemotherapy). But 54% of the patients did 
not undergo all the three modalities. They have completed only partial 
treatment. Only 46% patients had completed all the three modalities of 
treatment. 
Surgical excision of 
tumor And    v-p shunt 
only v-p shunt   
(no surgery ) 
Total 
candidates 
65 (87%) 10 (13%) 75 
In surgical category, 65  patients(87%)  have undergone  
ventricular -peritoneal shunt  along with  subtotal / near total excision of 
intracranial tumor (34 male;  31 female) . 10  patients (13%) had 
undergone  only ventricular -peritoneal shunt where no tumor excision 
was done.   (8 male; 2 female). 
Total number of patients treated with Radiation was 47 ( 62.6%)  
out of which  27 were males and  20  were   female. 28 patients  were  
not  given radiotherapy ,due to age  less than 3 years and treatment 
default  15 male   (35%) and 13 female ( 48.4% ). 
Radiotherapy Male patients Female patients Total patient 
Treated 27 20 47( 62.6%) 
Not treated 15 13 28(37.3%) 
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In radiotherapy arm,   patients were given craniospinal irradiation 
for 36 gy followed by boost to posterior fossa   up to 54 gyms. Cranium 
was treated by opposing lateral field.  Spinal irradiation was given by 
single PA in two fields, separated by 1 cm distance. Field shifting was 
done in feather technique in upward direction.  
In chemotherapy arm, 50 patients (66.6%) received chemotherapy 
(32 male and 18 female). Patients  received  weekly  inj.vincristine (1.2 
mg/m2)  concurrently   with  radiation followed by  adjuvant  
chemotherapy of  PCV regimen  once in  28 days for  6 cycle. 
(inj.cisplatin 75 mg/m2 IV day 1,inj.cyclophosphamide 1000 mg/m2 
days 22, 23 and  inj.vincristine 1.5 mg/m2 IV bolus max.2 mg days 
2,8,15.) Weekly inj.vincristine is not given to adult patients since the 
toxicity symptoms are more.  25 patients (33.3%) didn’t receive 
chemotherapy (10 male and 15 female) 
Chemotherapy Male Female Total 
Given 32 18 50(66.6%) 
 Not given 10 15 25(33.3%) 
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This is the ven diagram showing the total treatment pattern. Total 
number of patients treated is 75. Surgery modality is “considered 
complete” if the patient has completed total excision or near total 
excision.  Patient is   considered as “surgically incomplete” if he has 
undergone just biopsy or subtotal excision.  65 patients have undergone 
total or near total surgery. Patients undergone only biopsy or subtotal 
excision is 10.among the 65 cases that completed surgery, 20 patients 
didn’t undergo any other modality. SURGERY ONLY completed 
patients are 20 in number(7 male + 13 female). 3 patients underwent 
radiotherapy also( Surgery+ radiotherapy= 3) 8 patients undergone 
chemotherapy in addition to surgery(surgery+ chemotherapy=8).  
Number of patients given radiotherapy is 47.Among them number 
of patients given only radiation is 2.number of patients given 
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radiotherapy and chemotherapy is 5.(radiotherapy+ chemotherapy=5) 
Number of patients given only chemo therapy is 3. Number of patients 
given all the three treatment modality is  34. 
SINGLE MODALITY TREATMENT 
25 cases out of 75 cases (33.33%) completed only one modality, 
surgery, radiotherapy or chemotherapy.  
Only surgery completed : 7 male+ 13 female 
Only chemotherapy : 3 male+ 0 female 
Only radiotherapy given : 0 male+ 2 female 
BI- MODALITY TREATMENT 
16% of total cases completed double modality of treatment. They 
underwent surgery+ radiotherapy (or) radiotherapy + chemotherapy (or) 
surgery + chemotherapy. 
Surgery + chemotherapy completed : 5 males+ 3 female 
Chemotherapy+ radiotherapy  : 4 males+ 1 female 
Surgery + radiotherapy   : 3 male + 0 females 
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COMBINED TRI- MODALITIES TREATMENT 
Only 45.3% of patients completed all the three modalities, 34 
patients / 75 patients.  = 20 males and 14 females.  
 
Among the treatment modalities, 25 patients underwent only one 
type of treatment modality, (20- undergone surgery alone, 3 underwent 
chemo alone and 2 underwent radiotherapy alone.) 16 patients 
undergone bimodality approach, either surgery with chemo, or chemo 
with radiotherapy or radiotherapy and surgery. Only 34 underwent all 
the three modalities in right time. 
Surgery, RT,chemotherapy Male female Total 
Single modality completed 10 15 25 (33.3%) 
Bi modality completed 12 4 16 (21%) 
All the three modalities completed 20 14 34 (45%) 
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COMPILATION OF TREATMENT HISTORY 
 
47% of male and 42.42 % of females completed the full treatment 
with maximum safe excision, radiotherapy and chemotherapy. They 
constitute 45% of total study group. 52% of male and 57 % of female 
undergone only partial treatment. They didn’t undergo any one or two 
methods of treatment. They constitute 54.66%. 
When we compare the percentage of treatment completed 
category, with percentage of those who didn’t complete the treatment, 
the second one is more than the first one.  
% of treatment completed patients < % of patients with incomplete 
treatment 
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DEFAULTERS 
In individual arms among surgery, radiotherapy and 
chemotherapy, surgery is the arm in which highest % of patient’s 
undergone treatment (87%). Only 13 % of patients were not operated. 
Radiotherapy arm has lowest enrollment of patients (62.6%). In 
radiotherapy arm 37.4% defaulters present. The chemotherapy arm has 
66.6% of enrollment and 33 % defaulters.  
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REASON OF TREATMENT DEFAULT  
1. Lack of awareness about different modalities that should be 
incorporated. Care givers fail to enlighten the patients regarding the 
treatment protocol and follow-up.  (42%).  “ Lack of coordination 
among different treating surgeons and physicians” is one of the factors 
for patient’s lack of interest in treatment. 56% of defaulters expressed 
that, they are not aware of the correct schedule of the treatment.  
2. False belief of poor outcome of patient in the treatment (28%). 
Outright expressions of    poor prognosis by the treating physicians 
sometimes force the patient and family members to default the treatment. 
It discouraged them to proceed with the treatment further.  
3. Fear of toxicity during the treatment especially during 
chemotherapy and radiotherapy. 
4. Lack of adequate follow up facility. 
Establishment of a central monitoring committee among the 
different departments of treatment will ensure complete treatment in 
each individual without fear of drop out.  
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SURVIVAL RATES 
SURVIVAL CURVE COMPARISIONS 
1) Survival Between treatment completed group vs. incomplete 
treatment group. 
2) Comparison between - survivals in single modality treatment 
Vs. 
-double modality survival 
Vs. 
-survival of trimodality treatment approach 
3) Survival comparisons between adult and pediatric patients. 
4) Survival between histological subtypes. 
5) Survival between patients having centrally located tumors and 
laterally located tumors. 
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FOR SINGLE MODALITY TREATMENT COMPLITION 
 
Those who completed only surgical modality of treatment (i.e., 
under gone excision of tumor) the survival maximum was 26 months . 
Minimum survival was 3 months. Mean survival was 8.1 month. (7 male 
+ 13 females). Only chemotherapy undergone patients, (3 males only) 
the maximum survival was 18 months.  Minimum survival was 9 
months. Mean survival was 7.14 months. Only radiotherapy undergone 
patients, (2 females only) the maximum survival was 26 months. 
Minimal survival was 10 months. Mean survival was 11.7 months. 
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Treatment modality Mean survival of life 
Surgery alone 8.1 months 
Chemotherapy alone 7.14 months 
Radiotherapy alone 11.7 months 
On the whole the mean survival for single modality approach is 
8.27 months. 
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TWO MODALITY COMPLETED PATIENTS -SURVIVAL 
RATES 
Maximum survival and minimum survival rates 
 
In patients who undergone surgery and chemotherapy (5 male and 
3 female) the maximum survival was 40 months. Minimum survival was 
12 months. Mean survival was 16.1 months. 
With surgery and radiotherapy   (3 male only), the reported 
maximum survival was 20 months. Minimum survival reported was 8 
months. Mean survival was 9.6 months 
While radiotherapy and chemotherapy approach, (4 male and 1 
female) gave maximum survival of 48 months, which was the highest 
survival among double modality treatment undergone patients. Minimum 
survival was 16 months, mean survival was 17.88 months. 
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Treatments  undergone Mean survival rate 
 Surgery and chemo therapy 16.1 month 
Surgery and radiotherapy 9.6 month 
Radiotherapy and chemotherapy 17.88 months 
As a whole the mean survival for bi modality approach is 15.43 
months. 
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TREATMENT COMPLETED IN ALL 3 MODALITIES: 
SURVIVAL RATE 
 
Here we can compare the survival rates of patients who completed 
treatment, and the survival of those with incomplete treatment.  
Survival rates 
Treated with  
surgery, chemo and RT 
Incompletely  
treated patients 
2 year survival 91.2% (31/34) 19.3%(6/ 41) 
5 year survival 79.4% (27/34) - 
10 year survival 50 % (12/24)  
15 year survival 50 % (4/8) - 
The two year survival rate of treatment completed patients – 
91.2% (31/34).The two year survival rate of incompletely treated 
patients – 19.3% (6/41). The 5 year survival of patients who completed 
treatment – 79.4% (27/34). The 5 year survival rate of patients treated 
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incompletely – 0% (none alive out of 41). The 10 year survival rate of 
patients who completed treatment- 50 % (12/24). 
The mean survival comparison between single modality, bi -
modality completed patients and tri -modality completed patient: 
 
Total number of patients till 2008 was 58. Among those patients, 
total number of treatment completed patients was 24, who survived for 
10 years. There is no 10 year survival rate for incompletely treated 
persons. During the year 2001- 2003 we have treatment completed list of 
patients, which comprises of 8 members out of 16 total members.Among 
these 8 persons, one person died during the year 2017. So the 15 year 
survival rate in treatment completed persons: 4/8 which is 50 % if 
complete treatment is given. 
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Pediatric Vs. adult medulloblastoma 2 yr., 5 yr. and 10 yr. 
survival rates: 
We have totally 52 pediatric cases. It comprises of 31 male and 21 
female. Age less than 3 years 13 patients, (6 male and 7 female). In the age 
group of 4 to 12 years we have 39 cases, (25 male patients and 14 females). 
Survival rates Pediatric cases Adult cases 
 2 year survival 59% 21% 
 5 year survival 44% 21% 
10 year survival 28% 10% 
 
The survival rate was calculated among the pediatric cases, 2 year 
survival rate 59%, 5 years survival rate 44% and the 10 year survival rate 28%. 
We have 23 cases in adult patients in study. ( 11 male and 12 
female ) the 2 year survival rate 21%, 5 years survival rate 21 %, 10 
years survival rate 10%. 
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HISTOLOGICAL VARIANTS SURVIVAL RATES 
We have 5 histological types of histological varieties. They are classic, 
desmoplastic, large cell,anaplastic and nodular  . Among them, classical variant 
constitute more. The survival rates of these varieties are as follows: 2 year 
survival rate of nodular/large cell variety is 54%, 5 year survival tare is 18% 
and 10 year survival rate is 9%. Desmoplastic variant has better prognosis, 84% 
of 2 year survival rate, 5 year survival rate is 61% and 10 year survival rate is 
45%. Classical histological variety has 2 years survival rate – 67%, 5 year 
survival rate – 45% and 10 years survival rate is 15% 
Survival rates 
Classical 
histology 
Large 
cell/nodular 
Desmoplastic 
variety 
2 years survival 67% 54% 84% 
5 year survival 45% 18% 61% 
10 years survival 15% 9% 15% 
 
In this chart, desmoplastic has highest 2 year and 5 year survival. 
10 years survival becomes equal. Nodular/large cell variety has 
comparatively poor prognosis. 
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LATERALIZED TUMORS SURVIVAL RATES 
Totally 15 patients were lateralized tumor patients, situated in 
cerebral hemispheres, pediatric cases 2 male and 2 female.  Adult cases 
11 cases 6 males and 5 females. 
2 years survival rates:  8/ 15 = 53%. 5 year survival rates:  2/ 15 = 13%. 
Survival rate Number of cases % 
2year survival 8/ 15 53% 
5 year survival 2/ 15 13% 
10 year survival 0 0 
MIDLINE TUMOR SURVIVAL RATES 
We have 60 patients presented with midline tumors. The survival 
rates of those patients are 66% of 2 year survival rate, 41% 5 year 
survival rates, and 11% of 10 years survival rate. 
Survival rates Number of patients Percentage 
2 year survival 40/60 66% 
5 year survival 25/ 60 41% 
10 year survival 7/ 60 11% 
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RECURRANCE IN MEDULLOBLASTOMA PATIENTS  
Out of total 75 patients, 7 had recurrence (3 loco regional and 4 
distant recurrence) common features observed 
 The period of recurrence ranges from 1- 9 years. Mean 4-5 years. 
 Delay in  adjuvant treatment following  surgery/ incomplete 
treatment 
 Local recurrence seen  in posterior fossa 3_/ 7  
 Distal recurrence seen  in the body1)Bone and bone marrow 
indolent (mandible and spine metastasis) & viscera 
(hepatospenomegaly) 
 Mostly in male (5:2) and in nodular variety 
Age at 
presentation 
Year of 
presentation 
Year of 
recurrence 
Site of  
recurrence 
histology 
7 year/ 
Female 
2001 2005 Posterior fossa classical 
12 yr/ male 2001 2006 Posterior fossa desmoplastic 
19 yr / male 2004 2013 spine nodular 
25 yr/ 
female 
2005 2006 hepato 
spleenomegaly 
Nodular 
12 yr/male 2008 2013 leptomeninges classical 
8 yr / male 2010 2015 Posterior fossa nodular 
10 yr / male  2010 2015 mandible nodular 
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Treatment completed persons Vs incomplete treatment 
persons – survival rates 
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QUALITY OF LIFE ASSESSMENT IN 
MEDULLOBLASTOMA SURVIVORS  
Patients were assessed for their quality of life by asking simple 
questionnaire, QLQ – C30 version of EORTC.This questionnaire 
consisted of 30 simple questions in vernacular language, easily 
understandable. Totally 9 patients attended this questionnaire session in 
DEPARTMENTAL REVIEW, 5 patients were assessed in their home 
visit. 
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THE RESULTS OF ASSESSMENT: 
1. During follow up   4 patients had short stature. Three  patients 
have obesity. Patients had reported with significant alopecia, mainly 
occipital alopecia   None of our  patients    had      alopecia our patients 
did not have facial nerve palsy,   strabismus, hearing impairment, hemi -
and tetra paresis. 
2. Almost all patients had significant deficits in neurocognitive 
functioning: Attention and    processing speed were impaired   in   
almost all    patients, learning and    memory   impairments   were 
present in 9 patients who are presently alive. No patients  had language 
impairments or executivefunction impairments significant impairments 
in the overall level of intellectual functioning were seen in 10 patients. 
3. Patients experienced significant problems in school, forcing 
them to discontinue the  studies.  Few   patients attend regular schools, 
but needed  remedial teaching. 3 patients  were able to complete college 
education, but with low percentage of marks.   Treated  children though 
wish to participate in sports anplayful activities  but  unable  to    so  
because of fatigue and muscular weakness.  
They are able to carry out activities of   daily  life, like bathing 
without others support. They experienced difficulty in walking   for  
short distance (2 kilometers) and lifting articles weighing more than 5 
 61 
kg. Few are  able  to carry out manual jobs like shops vendors Boys are 
doing shop assistant jobs, where they do normal physical activities.no 
one had  Hearing impairment.  
4)  7 persons had visual impairment. They needed refractory 
lenses for visual correction. No patient developed cataract.  
5)90% of persons have aggressive   behavior and irritable 
personality. They experience difficulty in having friendly relationship 
with others forcing them to be isolated among their peer group. Majority 
of patients experience emotional distress and physical discomfort during 
socializing. They wish to spend day time sleeping, even though 
nocturnal sleep disturbance are present. 
6. Majority of them are not satisfied with their physical 
appearance. They feel they are shorter than their comparative age group. 
They display their displeasure towards physical beauty.  
7. Majority of them experience difficulty in learning. They study 
lesser classes than their corresponding age group. They feel difficulty in 
understanding the lessons. Many discontinued their studies.  
8. Majority of them don’t want to disclose about their disease to 
friends and relatives. Many don’t even want to give their photograph. 
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9. Bowel habits are often not normal, either constipation or 
irritable bloated abdomen present.They don’t want to take treatment for 
any health issue for fear of experiencing pain.  
10. Female patients are interested in family life with marriage. 
66% of patients attained menarche. They have regular menstruation. 
There is a delay in secondary sexual characteristic appearance, like, 
axillary and pubic hair growth and breast development.  
11. But majority of male patients consider the future married life 
as impossible. They have almost no moustache development. They are 
comparatively short. Majority don’t want to get married. Majority grade 
their quality of life as poor. 
 12. The patients of medulloblastoma have the following late 
complications. 
 Ideas about life partner- 80%                                         
 Difficulty in learning-69% 
 Interpersonal relationship-62%                                      
 Cosmetic disfigurement-33% 
 Aggressive nature, irritable –33%                                   
 Visual impairment- 25% 
 Sports activities -0% 
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DISCUSSION 
It  is  clearly  understandable , medulloblastoma  is  a  notorious  
tumor arising  from posterior fossa in vermin  of cerebellum.  The 
treatment of medulloblastoma has major challenges and yet remains a 
major frustration to the treating oncogist. Chennai is the capital city of 
Tamil and state, we have cases being referred from 7 districts from north 
Tamilnadu often.   
From southern Tamilnadu, cases come to RGGGH radiation 
oncology department, by their own wish. Cases from Chengalpattu, 
thiruvannamalai, vilupuram, cuddalore, nagapattinam, perambalur and 
thiruvallur districts reach our hospital for oncological treatment. Our 
study starts from January 2000 to December 2010. The cases treated in 
oncological department of madras medical college, were taken for 
analysis. 
The male: female ratio reported in this study is 4: 3.  Total 
number of males treated was 42 and the total number of females treated 
was 33. There is no specific reason for the male preponderance. There is 
a theory of loss of X chromosome is told for Group 4 histology.  
A significant expression of estrogen receptor beta, and no 
expression of estrogen receptor alpha, and low androgen receptors, 
found in medulloblastoma cell line, the tumor in female shows 
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differentiation, low Ki 67 and low p53 expression. This is proven in 
animal model, not in human. (53) 
The earliest age at presentation was 3 months (female baby).In  
this age patient can be treated with surgery and chemo alone. We can 
postpone RT by managing the   patient on   chemo therapy.  Infants if 
have larger primaries, the prognosis is very poor. They are poor 
candidates for intensive   chemotherapy   with    high dose     
methotrexate /      autologous    stem    cell transplantation; these 
patients are for complete resection only . sodium valproate can be used 
to keep away seizures in these babies.  
Incidence was highest in patients aged 1-4 years at diagnosis, but 
patients aged 10-14 years showed increased incidence durig the year 
2001- 2013.male showed increased incidence from 2000 to 2013 AS PER 
ONE STUDY(13) . In our study also it happens.  In our study: Total 
number of patients reported in the age group of 1-3 years, was 13. (6 
male and 7 female).  
In 4-12 years of age, 39 cases were reported (25 male and 14 
female). In 13- 18 years of age, 12 cases were reported (4 male and 8 
female). Less than 19 years of age group, 11 cases were reported (7 male 
and 4 female). The total number of male was 42, and female was  33. 
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The maximum age at presentation was 35 years (1 male and 1 
female). Usually   adult has a favorable prognosis than pediatric age 
group. Usually adult has desmoplastic variety, in histological 
classification and WNT subtype in molecular classification.  The only 
defect in adult is, we do not give weekly in vincristine, due to increased   
complication.  In pediatric group, shh and group 3 are common.  
Maximum cases reported in “4- 12 years “category (25 males and 
14 females). There is a concept of gonadotropin deficiency following 
craniospinal irradiation in medulloblastoma; puberty will be in 
appropriate time in half of patients, whereas few patients can have delay in 
puberty. A study says complete or partial gonadotropin deficiency can be a 
consequence of craniospinal irradiation, if it goes beyond 60 gyms. (54) 
Head ache is the commonest presentation (78%). Brain tumors as 
such cannot cause pain sensation, because brain is incapable of sensing 
pain. Brain has no pain receptors. Only when the tumor becomes  larger 
and produce compression over nerves and vessels, they cause head ache.  
When the tumor causes compression over the CSF flow, it can increase 
intra cranial pressure, which can cause headache. Usually the tumor 
headache will be worsen  in  the morning, aggravated  by coughing  
straining  shouting, not manageable by pain killers.  
Vomiting relieves the headache: vomiting is also a common 
symptom   (73%). It is told, vomiting can be a first neurological sign of 
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brain tumors in children. Chronic vomiting may be due to   increased 
intra cranial tension which leads to electrolyte imbalance. Tumor can 
because seizures caused due to cerebral irritation in 9.3%of patients.  
Some nonspecific features also present, deviation of angle of mouth due 
to 7 the nerve involvement, fever, drowsiness. They constitute 6.6% of 
clinical presentation. Involuntary micturition, weakness of limbs, 
tremors, nasal regurgitation also present in 2.6%.  
Among the histological variants, large cell and anaplastic variants 
are notorious for    unfavorable prognosis.  Desmoplastic   variant goes 
towards   favorable prognosis. In  adult  3  molecular  types  are  seen 
mostly- SHH   type  (60-65%),   Group D   ( 20-25%), and WNT (10-15%). 
Group  C  is  almost  exclusively  present  in  pediat ric  and 
adolescent group. Germ line mutation of fused homolog (SUFU) causes 
sonic hedgehog medulloblastoma especially in first few years of life. 
This is much worse in prognosis, when compared with SHH 
medulloblastoma.  
Transcriptional profiles of medulloblastoma tumors are done to 
identify the molecular subtype. If IHC for DKK1 is positive, it is WNT 
subtype. If IHC is positive for SFRP1, it is SHH subtype. If IHC is 
positive for NPR3, then it is group C. And if it is positive for KCNA1, it 
is group D. Group C has very less PFS. We didn’t analyses the samples 
on the basis of molecular subtypes. 
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The distribution according to staging (CHANG   STAGING) 
Stage Description No of patients 
M0 No evidence of subarachnoid metastasis 65 cases 
M1 Tumor cells in CSF 3 cases 
M2 Intracranial tumors beyond the primary site 5 cases 
M3 Seeding in spinal subarachnoid space 1 case 
M4 Extra neural spread 1 case 
M0 is without any metastases, in  our  study  we  have  65  cases  
in  M0  stage. M1 stage is presence of tumor cells in CSF. It can be seen 
in MRI or by CSF cytology. We have 3 cases in M1 stage. M2 is having 
gross nodular seeding in cerebellar, cerebral subarachnoid space third 
and fourth ventricle, i.e. other than primary site intra cranially. We have 
5 cases in M2 staging. M3 stage consists of gross nodular seeding in 
spinal subarachnoid space, we have 1 case reported. M4 is extra neural 
metastasis. We have 1 case in M4 stage.  
In adult medulloblastoma with leptomenigeal spread, pre radiation 
chemo therapy can increase the overall response and decrease the long 
term survival rates. The primary reason for treatment failure in 
medulloblastoma is the development of leptomeningeal metastasis. 
There are some methods to assess the seeding. MRI spine screening or 
CSF analysis can be done. It is said high levels of vascular endothelial 
cell growth factor and micro – RNA-210 are seen in medulloblastoma 
and its metastatic regions. Micro –RNA 210 can be analyzed by reverse 
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transcription quantitative polymerase chain reaction. VGFR m RNA can 
be assessed by western blot.in some instances, synchronous 
subarachnoid aneurysmal hemorrhage occurred in medulloblastoma 
patients at the site of metastasis. (It is very rare)  
Tumor seeding is considered negative prognostic factor. The 
seedlings may be in spinal compartment, infra tentoria or supra tentoria 
compartments. Spinal compartment seeding patients have a long 
progression free survival (PFS). Their overall survival is also   better. 
Majority of tumors are seen in midline (81.3%). We have 60 patients 
presented with midline tumors. The survival rates of those patients are 
66% of 2 year survival rate, 41% 5 year survival rates, and 11% of 10 
years survival rate. 
MIDLINE TUMORS 
Survival rates Number of patients Percentage 
2 year survival 40/60 66% 
5 year survival 25/ 60 41% 
10 year survival 7/ 60 11% 
Only 21% of cases are seen as lateral tumors. Totally 15 patients 
were lateralized tumor patients, situated in cerebral hemispheres, 
pediatric cases 2 male and 2 female. Adult can 11 cases- 6 males and 5 
females.2 years survival rates:  8/ 15 (53%); 5 year survival rates:  2/ 15 
(13%). Whereas for centrally located tumors, the survival rates are 2 
year survival is 66%, 5 years survival rate is 41%, and 10 year survival 
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rate is 11%.Total number of cases of midline tumors are given in the 
table 
Among medulloblastoma   patients, there  is  a  huge  difference 
between  the treatment completed  arm  and  the  incompletely  treated  
arm. If the patient is treated with single arm his life expectancy would 
be around 7- 9 months. If he had completed two modalities the survival 
increases almost twice, around 16-18 months. In contrast to the previous 
two categories, the survival increases up to 64-66 months if he 
completes all 3 treatment modalities.  
REASONS FOR NON-COMPLETION OF TREATMENT 
1. Lack of awareness about different modalities that should be 
incorporate. Care givers fail to enlighten the patients regarding the 
treatment protocol and follow-up.  (42%). Lack of coordination among 
different treating surgeons and physicians is one of the factors for 
patient’s lack of interest in treatment. 56% of defaulters expressed that, 
they are not aware of the correct schedule of the treatment.  
2. False belief of poor outcome of patient in the treatment (28%). 
Outright expressions of    poor prognosis by the treating physicians 
sometimes force the patient and family members to default the 
treatment... It discouraged them to proceed with the treatment further.  
3. Fear of toxicity during the treatment especially during 
chemotherapy and radiotherapy. 
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4. Lack of adequate follow up facility.  
Establishment of a central monitoring committee among the 
different departments of treatment will ensure complete treatment in 
each individual without fear of drop out.  
54% (52% male and 57% female) of the patients did not undergo 
all the three modalities.45% of patients completed full treatment. (47% 
male and 42.42 % female). When we compare the percentage of 
treatment completed category, with percentage of those who didn’t 
complete the treatment, the second one is more than the first reason for 
not completing treatment. 
Those who completed only surgical modality of treatment (i.e., 
under gone excision of tumor) mean survival was 8.1 month. Only 
chemotherapy undergone patients, Mean survival was 7.14 months .only 
radiotherapy undergone patients, mean survival was 11.7 months.  
Surgery and chemotherapy mean survival was 16.1 months. 
Radiotherapy and chemotherapy approach, mean survival was 17.88 
months. The survival in those who completed all the three modalities, 
mean survival was 5.4 years.  5 year survival rate- 79.41 % (27/ 34) 10 
year survival rate -35.29 % (12 / 34). The 15 year survival rate in 
treatment completed persons: 4/8 which is 50 % if complete treatment is 
given. 
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With surgery and radiotherapy   mean survival was 9.6 month . 
As per the  study “Outcome of Medulloblastoma in  Children: 
Long-Term Complications  and Quality of  Life Article  in 
Neuropediatric  June  2006 “ 
The mean follow-up time of all 51 patients following primary 
surgery was 6.6 years (range: 0.1 to 24.0 years). The 10-year overall 
survival was 53% and the 10-year progression-free survival was 40% as 
determined by the Kaplan-Meier method [26];. In our study, the follow 
up period ranges from 1 year to 17 years. Our study group is slightly 
larger. 75 patients. Our 2 year survival was 91-2%; 5 years survival 
76.4% and 10 year survival 50%.44% patients had short stature. In our 
study we experienced short stature in 4 patients. Facial nerve palsy, 
strabismus, hearing impairment, visual impairment, hemi-and tetra 
paresis, present in their study, none of our patients have such cranial 
nerve palsy or hearing impairment. Visual impairment we had in 5 
patients. Thirteen (72%) patients experienced significant problems in 
school. 
90% of persons have aggressive   behavior and irritable 
personality. They experience difficulty in having friendly relationship 
with others forcing them to be isolated among their peer group. Majority 
of patients experience emotional distress and physical discomfort during 
socializing. They wish to spend day time sleeping, even though 
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nocturnal sleep disturbance are present. Almost all patients had 
significant deficits in neurocognitive functioning:  
Attention and    processing speed were impaired   in   almost all 
patients, learning and   memory impairments were present in 9 patients 
who are presently alive. No patients had language impairments   or 
executive function   impairments significant impairments in the overall 
level of intellectual functioning were seen In 10 patients. 
Patients experienced significant problems in school, forcing them 
to discontinue the studies.  Few   patients attend regular schools, but 
needed remedial teaching. 3 patients  were able to complete college 
education, but withlow percentage of marks.  
The treated children though wish to participate in sports and 
playfulactivities but unable to so because of fatigue and muscular 
weakness. They are able tocarry out activities of daily life, like bathing 
without others support. They experienced difficulty in walking for short 
distance (2 kilometers) and lifting articles weighing more than 5  kg. 
Few are able to carry out manual jobs like shops vendors boys are doing 
shop assistant jobs, where they do normal physical activities.no one had 
hearing impairment.  
7 persons had visual impairment. They needed refractory lenses 
for visual correction. No patient developed cataract. Majority of them 
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are not satisfied with their physical appearance. They feel they are 
shorter than their comparative age group. They display their displeasure 
towards physical beauty. Majority of them experience difficulty in 
learning.  
They study lesser classed than their age group. They feel 
difficulty in understanding the lessons. Many discontinued their studies. 
Majority of them don’t want to disclose about their disease to friends 
and relatives. Many don’t even want to give their photograph.  
Bowel habits are often not normal, either constipation or irritable 
bloated abdomen present They don’t want to take treatment for any  
health issue for fear of  experiencing  pain Female patients are interested 
in  family life with marriage. 69% of patients attained menarche. They 
have regular menstruation.  
There is a delay in secondary sexual characteristic appearance, 
like, axillary and pubic hair growth and breast development. But 
majority of male patients consider the future married life as impossible. 
They have almost no moustache development. They are comparatively 
short. Majority don’t want to get married. Majority grade their quality of 
life as poor. 
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CONCLUSION 
Although medulloblastoma is a tumor of high mortality, correct 
treatment with surgery, chemotherapy and radiotherapy can save the life 
of the patient to certain extent. Surgical approach with total excision of 
the tumor along with ventriculoperitoneal shunt (wherever it is required) 
should be done to all the patients. Within 3 weeks patients must be 
given radiation to brain and spinal cord along with posterior fossa 
boost.Chemotherapy should be included in schedule.  
The survival is better in pediatric age group, than the adults. 
Desmoplastic variant of histology carries very good prognosis, classical 
variant has average prognosis. Anaplastic and nodular variety has poorer 
prognosis. In this study no attempt was done to elicite the molecular 
varients of the tumors. Centrally located tumors carry better prognosis 
than the eccentrically located tumors. Prognosis depends on all these 
factors also. 
Attenders must be instructed abiut the tri modality approach in the 
initial registration itself. Medulloblastoma special  clinics must be 
created so that the patients are enrolled in the clinic and adequate 
treatment follow up is ensured. NGOs and voluntary organisations can 
be included in counselling the care takers about the disease prognosis 
and the correct line of management. Majority of the patients lost their 
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follow up. Some patients needed hormonal replacement, but they were 
not identified in time, so no hormone replacement was given.These 
issues can be easily solved by medulloblastoma clinics under an team of 
dedicated workers. 
Although it is a notorious tumor for life, patient’s attenders can be 
given a guarantee if the patient correctly undergoes the treatment 
schedule. 
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presented 
14. I have had my questions answered to my satisfaction. 
15. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should contact the investigator. By 
signing this consent form I attest that the information given in this document has been clearly 
explained to me and understood by me, I will be given a copy of this consent document 
 
Name and signature / thumb impression of the participant (or legal representative if 
participant incompetent) 
Name ________________ Signature_________________ Date________________ 
Name and Signature of impartial witness (required for illiterate patients): 
Name ________________ Signature_________________ Date________________ 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative obtaining consent 
Name ________________ Signature_________________ Date________________ 
 
 
  
   
S. No NAME Admission AGE SEX compltion SURGERY CHEMO RT
MIDLINE\ 
LATERAL
histology 15
 recurrence 
in 2004
DEATH Chang
1 INDHUMATHI 2001 7 2 1 1 1 1 1 cl 5 RECUR 2005 2006
2 PRIYANKA 2001 13 2 0 0 1 1 n 2 24 months
3 BHAVANI 2001 9 2 1 1 0 1 cl 2
4 RAMESH 2001 20 1 K 1 1 1 2 des 15
5 DIVYA 2001 10 2 2 1 1 1 1 n 15
6 LAVANYA 2001 4 2 3 1 1 1 1 cl 15
7 CHANDRU 2001 12 1 K 1 1 1 1 des 5 recurrence,  2006
8 BOOPALAN 2002 14 1 K 1 1 1 1 cl 4 M2
9 SENTHIL 2002 15 1 0 1 1 2 des 3
10 SUNIL 2002 2 1 0 1 0 1 n 1 11 months M2
11 NISHA 2002 11 2 0 1 1 1 n 5
12 KALAIVANAN 2002 10 1 K 1 1 1 1 cl 15
13 KARPAGAVALLI 2002 16 2 1 0 0 2 n 3
14 SURYA 2002 2 1 1 0 0 1 cl 1
died during 
radiotherapy
M4
15 VINOTH KUMAR 2003 10 1 1 0 1 1 cl 1 2004
16 DIVYA 2003 11 2 4 1 1 1 1 cl 0
17 LOGESH 2004 7 1 1 0 1 1 cl 2
18 BASHEER AHMED 2004 19 1 K 1 1 1 2 n 10 recurrence spinemets
19 BAGYALAKSHMI 2004 17 2 5 1 1 1 1 des 5
20 SUBASREE 2004 13 2 0 0 1 2 cl 2 13 months M2
21 TAMARAI SELVI 2004 6 2 6 1 1 1 1 cl 10
22 DAYAKARAN 2004 4 1 1 0 1 1 cl 2
23 ELUMALAI 2004 24 1 0 1 1 2 des 4
24 MOHAMMED BASHA 2004 12 1 K 1 1 1 1 cl 6
25 GANESH 2004 11 1 1 1 0 1 cl 2 34 months M2
26 GOPI 2004 13 1 K 1 1 1 1 cl 2
27 MOHANRAJ 2004 11 1 K 1 1 1 1 cl 3
28 RAJESWARI 2004 20 2 1 0 0 2 n 1
29 PRADEEP 2005 10 1 K 1 1 1 1 cl 10
30 ARULMOZHI 2005 4 1 0 1 1 1 cl 1
31 POORANI 2005 13 2 1 0 0 1 n 0
32 KALEEWARI 2005 25 2 1 0 0 2 n 0
drop mets d2-
d12
9 months M3
33 RAJA RAGUVARAN 2005 6 1 1 0 0 2 cl 0
34 SIVARAM 2005 3 1 1 1 0 1 cl 0
S. No NAME Admission AGE SEX compltion SURGERY CHEMO RT
MIDLINE\ 
LATERAL
histology 15
 recurrence 
in 2004
DEATH Chang
35 JAYAVEL 2005 24 1 1 0 0 2 n 0
36 SONIA 2005 2 2 1 0 0 1 n 0
37 pavithra 2005 8 2 7 1 1 1 2 cl 0 died during 7th# M2
38 PAVUN 2005 14 2 8 1 1 1 1 des 10
39 MRIDULA 2006 2 2 1 0 0 1 n 0
40 DINESH 2006 11 1 1 0 1 1 n 2
41 BALAJI 2006 8 1 K 1 1 1 1 cl 10
42 MOHAMMED SALEEM 2007 5 1 1 0 0 1 cl 5
43 ZENPUTRET 2007 2 2 1 0 0 1 n 0
44 KIRAN 2007 10 1 K 1 1 1 1 n 2
45 RAMMOHAN 2007 11 1 K 1 1 1 1 des 5
46 VANITHA 2007 6 2 9 1 1 1 1 cl 5
47 aswin 2008 13 1 0 1 0 1 n 0 9 months
48 ASIF 2008 2 1 1 1 0 1 n 2 rt deferred
49 THANIGAMALAI 2008 12 1 K 1 1 1 1 cl 5
leptomeningea
l 
dissemination 
for chemo
M3
50 VIDYASRI 2008 5 2 10 1 1 1 1 cl 5
51 ARTHI 2008 25 2 1 0 0 2 des 0
52 INIYAVAN 2008 6 1 K 1 1 1 1 cl 5
53 VASANTHA KUMAR 2008 6 1 1 0 0 1 cl 0
54 NAVYA 2008 2 2 1 0 0 1 cl 0
55 BALAKRISHNAN 2008 1 1 0 1 0 1 cl 0 17 months
56 THEJA 2008 5 2 11 1 1 1 2 cl 10
57  SYED BASHA 2008 1 1 1 1 0 1 n 4 M1
58 VENNILA 2008 35 2 1 0 0 1 n 1 8 months
59 PUGALENDI 2009 7 1 K 1 1 1 2 des 5
60 RAJESWARI 2009 4 2 12 1 1 1 1 des 2
61 THIRUNAVUKKARASU 2009 7 1 K 1 1 1 1 des 5
62 SRINITHI 2009 2 2 1 1 0 1 cl 0
63 SIVAKUMAR 2009 25 1 1 0 0 2 des 0
64 NOUSHAD ALI 2009 27 1 1 0 0 1 n 3 7 months M1
65 MALINI 2009 5 2 1 0 0 1 n 0 9 months
66 ABIRAMI 2009 13 2 1 0 0 1 cl 3
67 MUTHUKANNAN 2010 17 1 K 1 1 1 1 cl 5
68 JEEVANANDA 2010 8 1 0 1 1 1 n 5 recurence M1
S. No NAME Admission AGE SEX compltion SURGERY CHEMO RT
MIDLINE\ 
LATERAL
histology 15
 recurrence 
in 2004
DEATH Chang
69 JEYALAKSHMI 2010 12 2 13 1 1 1 1 cl 5
70 MUTHURAMALINGAM 2010 10 1 K 1 1 1 1 cl 5
recurrence 
mandible
71 THENMOZHI 2010 12 2 14 1 1 1 1 cl 5
72 HARIPRASAD 2010 7 1 K 1 1 1 1 cl 5
73 SURENDRAN 2010 12 1 K 1 1 1 1 des 5
74 SWETHA 2010 2 2 1 0 0 1 n 0 3 months
75 HEMAPRIYA 2010 2 2 1 1 0 1 n 0 23 months
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